Format

Send to

Choose Destination
J Antimicrob Chemother. 2003 Feb;51(2):367-71.

Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice.

Author information

1
Institute of Infections and Immunity, Floor C, West Block, University Hospital, Queen's Medical Centre, University of Nottingham, UK.

Abstract

OBJECTIVE:

To determine the ability of mastic monotherapy to eradicate Helicobacter pylori infection from mice.

MATERIALS AND METHODS:

The susceptibility of H. pylori SS1 to mastic was assessed by broth dilution determination of the MIC and MBC. Mice were inoculated intragastrically with either a suspension of H. pylori SS1 (n = 70) or brain-heart infusion broth alone (n = 10). Mice were given antimicrobial chemotherapy 4 weeks after infection and were administered the mouse equivalent of either 2 g of mastic twice daily for 7 days or a triple therapy regimen containing the mouse equivalent of 400 mg of metronidazole, 250 mg of clarithromycin and 20 mg of omeprazole twice daily for 7 days. Mice were killed either immediately or 1 month after the completion of treatment, and their stomachs cultured for H. pylori.

RESULTS:

The mastic MIC and MBC of H. pylori SS1 were 7.80 and 31.25 mg/L, respectively. The triple therapy regimen eradicated infection from 19 of 20 SS1-infected mice. Mastic failed to eradicate infection from any of the 18 SS1-infected mice (P < 0.001) and there was no signifi- cant reduction in gastric bacterial load in mice treated with this regimen.

CONCLUSION:

Despite reported beneficial effects in ulcer patients and the good in vitro activity of mastic against H. pylori, this compound is unable to eradicate H. pylori infection from mice.

PMID:
12562704
DOI:
10.1093/jac/dkg057
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center